Opinion|Videos|June 26, 2024
Communication of Duchenne Muscular Dystrophy Diagnosis and Coordination of Care
Author(s)Emma Ciafaloni, MD
A neurology specialist offers clinical insights on communicating with patients about the diagnosis of Duchenne muscular dystrophy and discusses the important role of neuromuscular disease specialists.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How do you communicate with patients about the diagnosis of Duchenne muscular dystrophy (DMD)?
- What are the roles of a primary care physician and a neuromuscular disease specialist in discussing the prognosis with the family?
- What are the roles of a primary care physician and a neuromuscular disease specialist in discussing the prognosis with the family?
Advertisement
Related to this article
All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.
The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.
New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.
New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
MDS Congress 2026: Late-Breaking Data Snapshot
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis
4
New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy
5